TRACON Pharmaceuticals, a leading clinical stage biopharmaceutical company, has unveiled robust financial results for the third quarter (Q3) ending September 30, 2023, propelling a significant upswing in the company’s stock.
At the time of this publication, TRACON Pharmaceuticals Inc stock (TCON) has witnessed a surge.
TRACON Pharmaceuticals Inc
Current Price: $0.25
Change : +0.09
Change (%): (53.75%)
Volume: 50.5M
Source: Tomorrow Events Market Data
As of September 30, 2023, cash, cash equivalents, and restricted cash stood at $7.8 million, reflecting a notable shift from the $17.5 million reported at December 31, 2022.
In the third quarter of 2023, research and development expenses amounted to $2.3 million, showcasing a marked decrease from the $4.1 million recorded in the same quarter of the previous year. This reduction is primarily attributed to the strategic decision to enroll only cohort C in the ongoing ENVASARC pivotal trial.
Similarly, general and administrative expenses for the third quarter of 2023 amounted to $1.3 million, down from $2.3 million in the third quarter of 2022. The reduction in expenses is chiefly due to a decrease in legal costs.
An additional boost to TRACON’s financial standing came in the form of a $2.0 million refund in arbitration success fees from their legal representation. This refund, coupled with the write-off of approximately $0.3 million in legal fees, contributed to a more favorable financial landscape for the company in the third quarter of 2023.
The financial report also highlights other income of approximately $13.0 million, correlating with the successful collection of an arbitration award during the same period.
In a significant turnaround, TRACON Pharmaceuticals reported a net income of $10.8 million for the third quarter of 2023, a stark contrast to the net loss of $6.4 million reported during the same period in 2022.
Charles Theuer, M.D., Ph.D., TRACON’s Chief Executive Officer, expressed optimism about the company’s progress, stating, “We are on track to complete enrollment of 80 patients treated with single-agent envafolimab in the ongoing pivotal ENVASARC trial this year. The data monitoring committee recommended the study continue as planned in September based on a review of 46 patients, and since then, more than 20 additional patients have enrolled. We expect to report updated response rate data before the end of the year, with final data anticipated mid-2024. We also expect to license our Product Development Platform to one or more companies this year to allow them to transform their clinical operations.”
TRACON Pharmaceuticals’ positive Q3 financial results promising developments in its pivotal trials are poised to reinforce its standing in the biopharmaceutical sector, driving increased investor confidence and positioning the company for future success.
